Pathogenic mechanisms of the anti-phospholipid antibodies;Mecanismos patogénicos de los anticuerpos antifosfolípidos

Reumatologia Clinica

Volumn 7, Issue 1, 2011, Pages 72-76

  Núñez Álvarez, Carlos A ^a   Cabiedes, Javier ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Anti 2Glycoprotein I antibodies; Anticuerpos anti 2Glicoprote na I; Anticuerpos antifosfol pidos; Antiphospholipid antibodies; Antiphospholipid syndrome; S ndrome de antifosfol pidos

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; PHOSPHOLIPID ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; DISEASE COURSE; HUMAN; INFLAMMATORY DISEASE; PATHOGENICITY;

ABORTION, HABITUAL; ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIGENS; BETA 2-GLYCOPROTEIN I; BLOOD COAGULATION; CELL ADHESION; CYTOKINES; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FEMALE; HUMANS; IMMUNITY, CELLULAR; INFLAMMATION; PREGNANCY; THROMBOPHILIA; THROMBOSIS;

EID: 78651361944     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2009.10.005     Document Type: Article

References (51)

1. Bowie E.J., Thompson J.H., Pascuzzi C.A., Owen C.A. Trombosis in systemic lupus erithematosus despite circulating anticoagulants. J Lab Clin Med 1963, 62:416-430.
2. Harris E.N., Gharavi A.E., Boey M.L., Patel B.M., Macworth-Young C.G., Loizou S., et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983, 2:1211-1214.
3. Hughes G.R.V., Harris E.N., Gharavi A.E. The anticardiolipin syndrome. J Rheumatol 1986, 13:486-489.
4. Alarcón-Segovia D., Delezé M., Oria C.V., Sánchez-Guerrero J., Gómez-Pacheco L., Cabiedes J., et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine 1989, 68:353-365.
5. Alarcón-Segovia D., Sanchez-Guerrero J. Primary Antiphospholipid Syndrome. J Rheumatol 1989, 16:482-488.
6. Mackworth-Young C.G., Loizou S., Walport M.J. Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder. Ann Rheum Dis 1989, 48:362-367.
7. Asherson R.A., Khamashta M.A., Ordi-Ros J., Derksen R.H.W.M., Machin S., Barquinero J., et al. The "primary" antiphospholipid syndrome: major clinical and serological features. Medicine 1989, 68:366-374.
8. McNeil P.H., Simpson R.J., Chesterman C.N., Krilis S.A. Antiphospholipid antibodies are directed against complex antigen that include a lipid binding inhibitor of coagulation: Β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990, 87:4120-4124.
9. Galli M., Comfurius P., Maasen C., Hemker H.C., De Baets M.H., Van Breda-Vriesman P.J.C., et al. Anticardiolipin antibodies directed not to cardiolipin but to plasma protein cofactor. Lancet 1990, 335:1544-1547.
10. Matsuura E., Igarashi Y., Fujimoto M., Ichikawa K., Koike T. Anticardiolipin cofactor(s) and differencial diagnosis of autoimmune disease (letter). Lancet 1990, 336:177-178.
11. Alarcón-Segovia D., Cabral A.R. The anti-phospholipid antibody syndrome: clinical and serological aspects. Baillières Clin Rheumatol 2000, 14:139-150.
12. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey S.R.L., Cervera R., et al. International Consensus statement on an update of the classification criteria for definite APS. J Thromb Haemost 2006, 4:295-306.
13. Cabiedes J., Cabral A.R., Alarcón-Segovia D. Clinical manifestations of the antiphospholipid síndrome in systemic lupus erythematosus patients associate more strongly with anti-Β2-glycoprotein I than with antiphospholipid antibodies. J Rheumatol 1995, 22:1899-1906.
14. Gómez Suarez E.I., Cabiedes J. Estandarización de un inmunoensayo de captura para la determinación de los niveles séricos de Β2GP-I en sujetos sanos y en pacientes con SaF primario y asociado a LEG. Tesis de Licenciatura. UAM-INCMSZ 2005.
15. Alarcón-Segovia D. Pathogenic potential of anti-phospholipid antibodies. J Rheumatol 1988, 15:890-893.
16. Espinoza G., Cervera R., Font J., Shoenfeld Y. Anthiphospholipid syndrome: pathogenic mechanism. Autoinmmun Rev 2003, 2:86-93.
17. Pengo V., Biasiolo A., Brocco T., Tonetto S., Ruffatti A. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thromb Haemost 1996, 75:721-724.
18. Oosting J.D., Preissner K.T., Derksen R.H.W.M., De Groot P.G. Autoantibodies directed against the epidermal growth factor-like domains of thrombomodulin inhibit protein C activation in vitro. Br J Haematol 1993, 85:761-768.
19. Mori T., Takeya H., Nishioka H., Gabazza E.C., Suzuki K. Β2-glycoprotein I modulates the anticoagulant activity of protein C on the phospholipid surface. Thromb Haemost 1996, 75:49-55.
20. Cosgriff P.M., Martin B.A. Low functional and high antigenic antithrombin III level in a patient with the lupus anticoagulant and recurrent thrombosis. Arthritis Rheum 1981, 24:94-96.
21. Lakos G., Kiss E., Regeczy N., Tarjan P., Soltesz P., Zeher M., et al. Antiprothrombin and antiannexin V antibodies imply risk of thrombosis in patients with systemic autoimmune diseases. J Rheumatol 2000, 27:924-929.
22. Pasquier E., Amiral J., de Saint M.L., Mottier D. A cross sectional study of antiphospholipid-protein antibodies in patients with venous thromboembolism. Thromb Haemost 2001, 86:538-542.
23. Nojima J., Kuratsune H., Suehisa E., Futsukaichi Y., Yamanishi H., Machii T., et al. Association between the prevalence of antibodies to beta(2)-glycoprotein I, trothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications. Clin Chem 2001, 47:1008-1015.
24. Reverter J.C., Tàssies D., Font J., Monteagudo J., Escolar G., Ingelmo M., et al. Hypercoagulable state in patients with antiphospholipid syndrome is related to high induced tissue factor expression on monocytes and to low free protein S. Arterioscler Thromb Vasc Biol 1996, 16:1319-1326.
25. Reverter J.C., Tàssies D., Font J., Khamashta M.A., Ichikawa K., Cervera R., et al. Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes. Arthritis Rheum 1998, 41:1420-1427.
26. Dobado-Barrios P.M., Lopez-Pedrera C., Velasco F., Aguirre M.A., Torres A., Cuadrado M.J. Increased levels of tissue factor mRNA in mononuclear blood cells of patients with primary antiphospholipid syndrome. Thromb Haemost 1999, 82:1578-1582.
27. Oosting J.D., Derksen R.H.W.M., Blokzijl L., Sixma J.J., de Groot P.G. Antiphospholipid antibody positive sera enhance endothelial cell procoagulant activity: studies in a thrombosis model. Thromb Haemost 1992, 68:278-284.
28. Branch D.W., Rodgers G.M. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome:a possible mechanism of thrombosis. Am J Obstet Gynecol 1993, 168:206-210.
29. Meroni P.L., Raschi E., Camera M., Testoni C., Nicoletti F., Tincani A., et al. Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome. J Autoimmun 2000, 15:237-240.
30. Pierangeli S.S., Colden-Stanfield M., Liu X., Barker J.H., Anderson G.L., Harris E.N. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 1999, 99:1997-2002.
31. Salmon J.E., Girardi G., Holers M. Complement activation as a mediator of antiphospholipid antibodies induced pregnancy loss and thrombosis. Ann Rheum Dis 2002, 61:46-50.
32. Pierangeli S.S., Espinola R.G., Liu X., Harris E.N. Thrombogenic effects of antiphospholipids antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1 and P-selectin. Circ Res 2001, 88:245-250.
33. Girardi G., Berman J., Redecha P., Spruce L., Thruman J.M., Kraus D., et al. Complement C5a receptors and neutrophils mediate fetal injury in the Antiphospholipid syndrome. J Clin Invest 2003, 112:1644-1654.
34. Pierangeli S.S., Girardi G., Vega-Ostertag M., Liu X., Espinola R.G., Salmon J.E. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005, 52:2120-2124.
35. Di Simone N., Raschi E., Testoni C., Castellani R., D'Asta M., Shi T., et al. Pathogenic role of anti-beta 2 glycoprotein I antibodies in antiphospholipid associated fetal loss: characterization of beta 2 glycoprotein I binding to trophoblast cells and functional effects of anti-beta 2 glycoprotein I antibodies in vitro. Ann Rheum Dis 2005, 64:462-467.
36. Shi W., Chong B.H., Chesterman C.N. beta-2-glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: differences with lupus anticoagulants. Blood 1993, 81:1255-1262.
37. Blank M., Krause I., Lanir N., Vardi P., Gilburd B., Tincani A., et al. Transfer of experimental antiphospholipid syndrome by bone marrow cell transplantation: the importance of the T cell. Arthritis Rheum 1995, 38:115-122.
38. Kuwana M. Autoreactive CD4+ T cells to beta-2 glycoprotein-I in patients with antiphospholipid syndrome. Autoimmun Rev 2003, 2:192-198.
39. Núñez-Álvarez C.A., Ortega A., Hernández-Ramírez D.F., Pascual-Ramos V., Martínez Castillo A., Cabral C., et al. Proliferación de células mononucleares de sangre periférica (CMNSP) de una paciente con SaFP inducida por Β2GP-I de fenotipo valina o leucina (V/L)247. Reumatol Clin 2008, 4:30.
40. Arai T., Yoshida K., Kaburaki J., Inoko H., Ikeda Y., Kawakami Y., et al. Autoreactive CD4+ T-cell clones to beta-glycoprotein I in patients with APS: preferential recognition of the major phospholipid-binding site. Blood 2001, 98:1889-1896.
41. Ito H., Matsushita S., Tokano Y., Nishimura H., Takana Y., Fujisao S., et al. Analysis of T cell responses to the beta2-glycoprotein I-derived peptide library in patients with anti-beta2-glycoprotein I antibody associated autoimmunity. Hum Immunol 2000, 61:366-377.
42. Prieto G.A., Cabral A.R., Zapata-Zuniga M., Simon A.J., Villa A.R., Alarcón-Segovia D., et al. Valine/valine genotype at position 247 of the ß2-glycoprotein I gene in Mexican patients with primary antiphospholipid syndrome: association with anti-ß2-glycoprotein I antibodies. Arthritis Rheum 2003, 48:471-474.
43. Núñez-Álvarez C.A., Hernández-Ramírez DF, Calderón B., Cabral A.R., Cabiedes J. Caracterización de clonas de linfocitos B obtenidos de una paciente con SaF Primario. Reumatol Clin 2009, 5:55.
44. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., Coffman R.L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. 1986. J Immunol 2005, 175:5-14.
45. Ouyang W., Kolls J.K., Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008, 28:454-467.
46. Krause I., Blank M., Levi Y., Koike T., Barak V., Shoenfeld Y. Anti-idiotype immunomodulation of experimental anti-phospholipid syndrome via effect on Th1/Th2 expression. Clin Exp Immunol 1999, 117:190-197.
47. Visvanathan S., McNeil P. Cellular Immunity to beta2-Glycoprotein-1 in patients with the Antiphospholipid Syndrome. J Immunol 1999, 162:6919-6925.
48. Karakantza M., Theodorou G.L., Meimaris N., Mouzaki A., John E., Andonopoulos A.P., et al. Type 1 and type 2 cytokine-producing CD4+ and CD8+ T cells in primary antiphospholipid syndrome. Ann Hematol 2004, 83:704-711.
49. Berman J., Girardi G., Salmon J.E. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol 2005, 174:485-490.
50. Hamid C., Norgate K., Cruz D.P.D., Kamashta M.A., Arno M., Pearson J.D., et al. Anti ß2GP-I antibody-induced endothelial cell gene expression profiling reveals induction of novel pro-inflammatory genes potentially involved in primary antiphospholipid syndrome. Ann Rheum Dis 2007, 66:1000-1007.
51. Stone S., Pijnenborg R., Vercruysse L., Poston R., Khamashta M.A., Hunt B.J., et al. The placental bed in pregnancies complicated by primary antiphospholipid syndrome. Placenta 2006, 27:457-467.